Genentech is teaming with Seattle based Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients . The latter uses scanning technology that can search the immune system for targets for cell therapies . Adaptive will check its library of T - cell receptors found by the tech to identify ones useful in therapies , which Genentech will then engineer and manufacture as part of the $ 300bn partnership . Genentech could ultimately pay over $ 2bn in milestones as the experimental drugs are developed . Xconomy Seattle — Genentech is paying Adaptive Biotechnologies $300 million up front in a new partnership focused on developing cancer immunotherapies personalized to individual patients. The San Francisco - based group will also deal with clinical testing , commercialisation and regulatory work . Adaptive will receive royalties from any therapies they market .
Genentech is teaming with Seattle based Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients . The latter uses scanning technology that can search the immune system for targets for cell therapies . Adaptive will check its library of T - cell receptors found by the tech to identify ones useful in therapies , which Genentech will then engineer and manufacture as part of the $ 300bn partnership . Genentech could ultimately pay over $ 2bn in milestones as the experimental drugs are developed . The San Francisco - based group will also deal with clinical testing , commercialisation and regulatory work . Adaptive will receive royalties from any therapies they market .